Image For Activity Cover
GRGUH2EM2301 - CME/CMLE - Challenges in Testing Across the HER2+ Breast Cancer Spectrum
Course Description

Microlearning Series: Challenges in Testing Across the HER2+ Breast Cancer Spectrum 

 This CME/CMLE-accredited, case-based microlearning activity is designed to help pathologists and laboratory professionals increase the knowledge, skills, and competence in testing and diagnosing breast cancer across the HER2 spectrum.  

 Every few days, participants will be emailed or sent several questions through the Qstream app.  Each question consists of an authentic patient case/scenario and an assessment question with 3-5 multiple-choice answers designed to prompt the participant to make an appropriate diagnosis/recommendation. 

 This case-based microlearning activity includes the following topics: 

 

  • Best practices in IHC interpretation across the HER2 spectrum in patients with breast cancer 

  • Clinical practice guidelines for IHC and ISH testing of HER2 in patients with breast cancer 

  • The science and emerging evidence around HER2-low breast cancer 

  • HER2 classification, tracking, and reporting considerations 

  • Emerging treatment options for patients with HER2-low breast cancer 

  • The critical importance of communication within the multidisciplinary cancer care team in the diagnosis and management of patients with breast cancer 

 The activity offers 1.0 CME/CMLE credit. 

Faculty/Authors

Swikrity U Baskota,MD, FCAP
Assistant Professor of Pathology and Cell Biology at Columbia University Medical Center
 
Poonam Vohra, M.D.
Associate Professor, Anatomic Pathology, University of California, San Francisco 

Physician's Competency: Patient Care, Medical Knowledge, Practice-Based Learning and Improvement  

CME/CMLE Credit: 1.0
Estimated Completion Time: 1.0 hour
Format: Online educational activity

Credit Designation Statement
The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.
 
The ASCP designates this online microlearning activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
 
ASCP designates this online microlearning activity for a maximum of 1.0 CMLE credit.  This activity meets CMP and state re-licensure requirements for laboratory personnel.
 
For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, during normal business hours: Monday through Friday, 8 a.m. to 6 p.m. Eastern Time 

Method of Participation
To complete the activity and receive credit, the participant must complete the online activity. CME certificates will be provided online.
 
Commercial Support

Funded by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

.
Instructions

To claim CME/CMLE credit for the exercise, do the following:

  1. Review the Technical Considerations.
  2. Click Go to Content to view an overview of the modules in this course.
  3. Complete the Demographic Survey.
  4. Submit the course Evaluation.
  5. Enter the maximum number of credits offered and click Claim CME/CMLE to register credit.

Faculty Disclosures 

Technical Considerations 

Release Dates: 1/13/2023   
Review Date:
Expiration Date: 1/13/2025   




Course Objectives

Upon completion of this activity, you will be able to:

  • Appropriately conduct IHC and ISH testing, classification, and reporting in routine and complex breast cancer cases across the HER2 spectrum in accordance with guidelines

  • Describe the science and emerging evidence around the diagnosis, testing, and treatment of patients with HER2-low breast cancer

  • Update laboratory processes and procedures (eg, related to identification, tracking, and reporting) to prepare for the anticipated emergence of HER2-low as a diagnostic category of breast cancer

  • Outline ways to improve communication and coordination among pathologists, oncologists, and other members of the cancer care team when discussing HER2 test results in patients with breast cancer




 

Summary
Availability: On-Demand
Credit Offered:
1 CME/CMLE Credit
Contains: 2 Courses
Powered By